Natalie Exner Dean

Natalie Exner Dean

Auto-generated profile, based on publicly available information

Natalie Exner Dean

Emory University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2020 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
AAAlberto Aleta
Alberto Aleta
DMDavid Martín-Corral
David Martín-Corral
APAna Pastore Y Piontti
Ana Pastore Y Piontti
MAMarco Ajelli
Marco Ajelli
MLMaria Litvinova
Maria Litvinova
YMYamir Moreno
Yamir Moreno

10 March 2022 in Science
Verified
Journal Article
Open access
KKKatia Koelle
Katia Koelle
MMMichael A. Martin
Michael A. Martin
RARustom Antia
Rustom Antia
BLBen Lopman
Ben Lopman
NDNatalie E. Dean
Natalie E. Dean
We have come a long way since the start of the COVID-19 pandemic—from hoarding toilet paper and wiping down groceries to sending our children back to school and vaccinating billions. Over this period, the global community of epidemiologists and evolutionary biologists has also come a long way in understanding the complex and changing dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. In this Review, we retrace our steps through the questions that this community faced as the pandemic unfolded. We focus on the key roles that mathematical modeling and quantitative analyses of empirical data have played in allowing us to address these questions and ultimately to better understand and control the pandemic.

13 November 2020 in Science
Verified
Journal Article
Closed access
PDF file
MLMarc Lipsitch
Marc Lipsitch
NDNatalie E. Dean
Natalie E. Dean
Vaccine efficacy in high-risk groups and reduced viral shedding are important for protection

11 February 2020 in medRxiv
Verified
Preprint
Open access
PDF file
YYYang Yang
Yang Yang
QLQing-Bin Lu
Qing-Bin Lu
MLMing-Jin Liu
Ming-Jin Liu
YWYi-Xing Wang
Yi-Xing Wang
AZAn-Ran Zhang
An-Ran Zhang
LFLi-Qun Fang
Li-Qun Fang
Our manuscript was based on surveillance cases of COVID-19 identified before January 26, 2020. As of February 20, 2020, the total number of confirmed cases in mainland China has reached 18 times of the number in our manuscript. While the methods and the main conclusions in our original analyses remain solid, we decided to withdraw this preprint for the time being, and will replace it with a more up-to-date version shortly. Should you have any comments or suggestions, please feel free to contact the corresponding author.

25 October 2021 in Nature
Verified
Journal Article
Open access
PDF file
JDJessica T. Davis
Jessica T. Davis
MCMatteo Chinazzi
Matteo Chinazzi
NPNicola Perra
Nicola Perra
KMKunpeng Mu
Kunpeng Mu
APAna Pastore Y Piontti
Ana Pastore Y Piontti
AVAlessandro Vespignani
Alessandro Vespignani
Considerable uncertainty surrounds the timeline of introductions and onsets of local transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) globally1–7. Although a limited number of SARS-CoV-2 introductions were reported in January and February 2020 (refs.8,9), the narrowness of the initial testing criteria, combined with a slow growth in testing capacity and porous travel screening10, left many countries vulnerable to unmitigated, cryptic transmission. Here we use a global metapopulation epidemic model to provide a mechanistic understanding of the early dispersal of infections and the temporal windows of the introduction of SARS-CoV-2 and onset of local transmission in Europe and the USA. We find that community transmission of SARS-CoV-2 was likely to have been present in several areas of Europe and the USA by January 2020, and estimate that by early March, only 1 to 4 in 100 SARS-CoV-2 infections were detected by surveillance systems. The modelling results highlight international travel as the key driver of the introduction of SARS-CoV-2, with possible introductions and transmission events as early as December 2019 to January 2020. We find a heterogeneous geographic distribution of cumulative infection attack rates by 4 July 2020, ranging from 0.78% to 15.2% across US states and 0.19% to 13.2% in European countries. Our approach complements phylogenetic analyses and other surveillance approaches and provides insights that can be used to design innovative, model-driven surveillance systems that guide enhanced testing and response strategies.

6 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
NGNicolò Gozzi
Nicolò Gozzi
MCMatteo Chinazzi
Matteo Chinazzi
NDNatalie E. Dean
Natalie E. Dean
IJIra M. Longini Jr
Ira M. Longini Jr
MHM. Elizabeth Halloran
M. Elizabeth Halloran
AVAlessandro Vespignani
Alessandro Vespignani
Access to COVID-19 vaccines on the global scale has been drastically hindered by structural socio-economic disparities. Here, we develop a data-driven, age-stratified epidemic model to evaluate the effects of COVID-19 vaccine inequities in twenty lower middle and low income countries (LMIC) selected from all WHO regions. We investigate and quantify the potential effects of higher or earlier doses availability. In doing so, we focus on the crucial initial months of vaccine distribution and administration, exploring counterfactual scenarios where we assume the same per capita daily vaccination rate reported in selected high income countries. We estimate that more than 50% of deaths (min-max range: [54−94%]) that occurred in the analyzed countries could have been averted. We further consider scenarios where LMIC had similarly early access to vaccine doses as high income countries. Even without increasing the number of doses, we estimate an important fraction of deaths (min-max range: [6−50%]) could have been averted. In the absence of the availability of high-income countries, the model suggests that additional non-pharmaceutical interventions inducing a considerable relative decrease of transmissibility (min-max range: [15−70%]) would have been required to offset the lack of vaccines. Overall, our results quantify the negative impacts of vaccine inequities and underscore the need for intensified global efforts devoted to provide faster access to vaccine programs in low and lower-middle-income countries.